learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forResearch
5 / 1000+ results
research Lipoatrophy and Severe Metabolic Disturbance in Mice with Fat-Specific Deletion of PPARγ
Mice lacking the PPARγ gene in their fat cells had almost no fat tissue, severe metabolic problems, and abnormal development of other fat-related tissues.
research Maternal PPARγ Protects Nursing Neonates by Suppressing the Production of Inflammatory Milk
A mother's PPARγ is crucial for preventing harmful milk that can cause inflammation and growth problems in babies.
research Physiological Functions of PP2A: Lessons from Genetically Modified Mice
Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.
research The Role of PPARγ-Mediated Signalling in Skin Biology and Pathology: New Targets and Opportunities for Clinical Dermatology
PPARγ is crucial for skin health but can have both beneficial and harmful effects.
research Peroxisome Proliferator-Activated Receptors (PPARs) and PPAR Agonists: The Future in Dermatology Therapeutics?
PPAR agonists show promise for skin conditions but need more research before being a main treatment.
Community Join
5 / 921 resultscommunity Why so much hate for PP405 all of a sudden?
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
community PP405 Phase 2a press release with early results
PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.
community Molecule PP405: A Research Team Backed By Google Ventures Has Discovered One Of The Most Promising Solutions For Hair Loss To Date
PP405 is a promising new treatment for hair loss that activates dormant stem cells in hair follicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
community UCLA scientists found a molecule — PP405 — that wakes up sleeping hair follicles and tells them, “Do your job.”
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
community My summation of PP405 - looks promising
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.